Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy
The poster entitled, “Relationship between N-acetylaspartate and neurofilament light chain in multiple system atrophy” was presented by Paula Trujillo Diaz, PhD, Research Assistant Professor, Department of Neurology, Vanderbilt University Medical Center.
- The poster entitled, “Relationship between N-acetylaspartate and neurofilament light chain in multiple system atrophy” was presented by Paula Trujillo Diaz, PhD, Research Assistant Professor, Department of Neurology, Vanderbilt University Medical Center.
- N-acetylaspartate (NAA) is a novel biomarker of neuronal integrity with potential for assessing disease severity, monitoring the course of disease, and evaluating the efficacy of disease modifying therapies in MSA.
- In the study, the data provided evidence that NAA correlates with levels of neurofilament light chain (NfL) in patients with early MSA.
- “The data presented at AAS reveals another potentially important biomarker for the evaluation of this rapidly progressive disease with no approved treatment.